Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Latini

Showing results (61-70 of 338) with videos related to

Pageof 34
Sort By:
Vascular Pharmacology|October 7, 2006
The long pentraxin PTX3 in vascular pathologyAlberto Mantovani, Cecilia Garlanda, Barbara Bottazzi, et al.
Atherosclerosis|June 21, 2025
Leukocyte-shed soluble CD31 unmasks coronary disease in low-risk outliers and provides source-specific inflammatory signatures of vulnerable plaquesMarco Magnoni, Daniele Andreini, Felicita Andreotti, et al.
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|June 11, 2005
[The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design]Giuseppe Cacciatore, Alessandro Boccanelli, Gian Francesco Mureddu, et al.
Coronary Artery Disease|November 21, 2012
Natriuretic peptides in acute chest pain and acute coronary syndrome: from pathophysiology to clinical and prognostic applicationsNadia Aspromonte, Stefania A Di Fusco, Roberto Latini, et al.
European Journal of Heart Failure|July 11, 2006
A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunctionJawdat Abdulla, Simona Barlera, Roberto Latini, et al.
Journal of the American College of Cardiology|September 13, 2008
Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)Serge Masson, Roberto Latini, Inder S Anand, et al.
Anesthesiology|May 18, 2013
Unilateral acid aspiration augments the effects of ventilator lung injury in the contralateral lungMaria Amigoni, Giacomo Bellani, Vanessa Zambelli, et al.
Cardiovascular Drugs and Therapy|August 17, 2019
Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study PopulationCarlo Bruno Giorda, Giovanni Cioffi, Donata Lucci, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 29, 2003
Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodelingLaura Calvillo, Roberto Latini, Jan Kajstura, et al.
European Journal of Preventive Cardiology|March 23, 2021
Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trialGiovanni Cioffi, Carlo Bruno Giorda, Donata Lucci, et al.
Pageof 34

Showing results (61-70 of 338) with videos related to

Sort By:
Pageof 34
Vascular Pharmacology|October 7, 2006
The long pentraxin PTX3 in vascular pathologyAlberto Mantovani, Cecilia Garlanda, Barbara Bottazzi, et al.
Atherosclerosis|June 21, 2025
Leukocyte-shed soluble CD31 unmasks coronary disease in low-risk outliers and provides source-specific inflammatory signatures of vulnerable plaquesMarco Magnoni, Daniele Andreini, Felicita Andreotti, et al.
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|June 11, 2005
[The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design]Giuseppe Cacciatore, Alessandro Boccanelli, Gian Francesco Mureddu, et al.
Coronary Artery Disease|November 21, 2012
Natriuretic peptides in acute chest pain and acute coronary syndrome: from pathophysiology to clinical and prognostic applicationsNadia Aspromonte, Stefania A Di Fusco, Roberto Latini, et al.
European Journal of Heart Failure|July 11, 2006
A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunctionJawdat Abdulla, Simona Barlera, Roberto Latini, et al.
Journal of the American College of Cardiology|September 13, 2008
Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)Serge Masson, Roberto Latini, Inder S Anand, et al.
Anesthesiology|May 18, 2013
Unilateral acid aspiration augments the effects of ventilator lung injury in the contralateral lungMaria Amigoni, Giacomo Bellani, Vanessa Zambelli, et al.
Cardiovascular Drugs and Therapy|August 17, 2019
Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study PopulationCarlo Bruno Giorda, Giovanni Cioffi, Donata Lucci, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 29, 2003
Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodelingLaura Calvillo, Roberto Latini, Jan Kajstura, et al.
European Journal of Preventive Cardiology|March 23, 2021
Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trialGiovanni Cioffi, Carlo Bruno Giorda, Donata Lucci, et al.
Pageof 34